The Treatment of Hormone Refractory Prostate Cancer

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1996 • 1,584 citations

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

1999 • 994 citations

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

1999 • 907 citations

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1993 • 421 citations

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.

1998 • 373 citations

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

2004 • 353 citations

Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

1999 • 318 citations

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

1997 • 274 citations

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1998 • 266 citations

THE BIOLOGY OF HORMONE REFRACTORY PROSTATE CANCER

1999 • 256 citations

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1991 • 247 citations

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.

1992 • 237 citations

Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone

1999 • 229 citations

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

1994 • 225 citations

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

1998 • 223 citations

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade

1997 • 222 citations

Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial

1999 • 211 citations

Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer

1992 • 206 citations

Importance of continued testicular suppression in hormone-refractory prostate cancer.

1993 • 195 citations

Morphometric Evidence for Bone Resorption and Replacement in Prostate Cancer

1991 • 192 citations

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone

2000 • 189 citations

Hormone-refractory (D3) prostate cancer: Refining the concept

1995 • 181 citations

Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer

1999 • 166 citations

High-dose intravenous pamidronate for metastatic bone pain

1994 • 166 citations

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1999 • 158 citations

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.

1994 • 157 citations

HER‐2 profiling and targeting in prostate carcinoma

2002 • 136 citations

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

2001 • 129 citations

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.

1994 • 118 citations

THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCER

2001 • 118 citations

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.

1988 • 114 citations

Growth factors and their receptors: new targets for prostate cancer therapy

2001 • 109 citations

An adjustment to the 1997 estimate for new prostate cancer cases

1997 • 108 citations

Complications for Radical Cystectomy

2001 • 106 citations

Ibandronate in the treatment of prostate cancer associated painful osseous metastases

2002 • 105 citations

A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain

1997 • 104 citations

Overview: hormone refractory prostate cancer

1999 • 103 citations

Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer

2000 • 85 citations

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.

1997 • 80 citations

Mechanisms of Action and Clinical Uses of Estramustine

1990 • 73 citations

A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer Patients

2001 • 70 citations

Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.

1983 • 65 citations

Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer

2001 • 54 citations

Current Status of Cytotoxic Chemotherapy in Hormone Refractory Prostate Cancer

2001 • 54 citations

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer.

1996 • 50 citations

Treatment Options in Hormone-Refractory Prostate Cancer

2001 • 46 citations

PROGNOSTIC INDICATORS IN HORMONE REFRACTORY PROSTATE CANCER

1999 • 35 citations

Evaluation of Estramustine Phosphate Combined With Weekly Doxorubicin in Patients With Androgen-Independent Prostate Cancer

1998 • 34 citations

Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma

1999 • 32 citations

European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976—1996

1998 • 31 citations

Combination of Epirubicin and Cisplatin in Hormone-Refractory Metastatic Prostate Cancer

1999 • 30 citations

Chemotherapy for hormonally refractory advanced prostate carcinoma. A Comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil

1992 • 26 citations

Docetaxel and exisulind in hormone-refractory prostate cancer

2001 • 23 citations

Doxorubicin, Mitomycin C and 5-Fluorouracil in the Treatment of Hormone Refractory Adenocarcinoma of the Prostate: A Southwest Oncology Group Study

1993 • 22 citations

Multidrug Chemotherapy in the Treatment of Non-Elderly Patients with Hormone-Refractory Prostatic Carcinoma

1996 • 20 citations

Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study

1997 • 15 citations

A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer Patients

2001 • 15 citations

Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone‐refractory prostate carcinoma

2003 • 13 citations

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

2004 • 7 citations

Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study.

2003 • 4 citations